(RTTNews) – Cassava Sciences, Inc. (SAVA), a clinical-stage biotechnology firm, that develops medicine for nervous system problems, is scheduled to report its fourth-quarter outcomes at this time, March 23.
On common, analysts polled by Thomson Reuters anticipate the corporate to report lack of $0.13 per share.
Within the third-quarter, the corporate had a optimistic earnings shock of $0.04 loss per share in contrast with loss per share of $0.13 in the course of the corresponding interval final yr.
The corporate’s lead drug candidate is PTI-125 proposed for the remedy of Alzheimer’s illness is in part IIb examine. Cassava expects to announce top-line outcomes by mid-year 2020.
Cassava can also be growing PTI-125Dx, a blood-based diagnostic to detect and monitor Alzheimer’s illness.
The corporate, as a rule, provides updates on scientific trials throughout quarterly outcomes.
Cassava Sciences ended the third quarter with $17.Eight million of money and equivalents, and no debt.
SAVA was down $0.36 or 8.51% on March 20, earlier than closing at $3.87. It has traded within the vary of $1.00- $10.95 within the final 52-weeks.
The views and opinions expressed herein are the views and opinions of the writer and don’t essentially mirror these of Nasdaq, Inc.
